FDA Panels Say Risks of Opana ER Outweigh Benefits FDA Panels Say Risks of Opana ER Outweigh Benefits

Members of the FDA ' s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products advisory committees conclude the abuse-deterrent oxymorphone ' s risks now outweigh its benefits.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news